CA2533177A1 - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction Download PDF

Info

Publication number
CA2533177A1
CA2533177A1 CA002533177A CA2533177A CA2533177A1 CA 2533177 A1 CA2533177 A1 CA 2533177A1 CA 002533177 A CA002533177 A CA 002533177A CA 2533177 A CA2533177 A CA 2533177A CA 2533177 A1 CA2533177 A1 CA 2533177A1
Authority
CA
Canada
Prior art keywords
vasopressin
compound
ejaculation
receptors
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533177A
Other languages
English (en)
French (fr)
Inventor
Christopher Peter Wayman
Rachel Jane Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2533177A1 publication Critical patent/CA2533177A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002533177A 2003-07-23 2004-07-12 Treatment of male sexual dysfunction Abandoned CA2533177A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction
GB0317227.7 2003-07-23
PCT/IB2004/002300 WO2005006899A1 (en) 2003-07-23 2004-07-12 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
CA2533177A1 true CA2533177A1 (en) 2005-01-27

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002533177A Abandoned CA2533177A1 (en) 2003-07-23 2004-07-12 Treatment of male sexual dysfunction

Country Status (12)

Country Link
EP (1) EP1656183B1 (https=)
JP (1) JP2006528171A (https=)
AT (1) ATE380048T1 (https=)
BR (1) BRPI0412255A (https=)
CA (1) CA2533177A1 (https=)
CL (1) CL2004001702A1 (https=)
GB (1) GB0317227D0 (https=)
MX (1) MXPA05014200A (https=)
TW (1) TW200510424A (https=)
UA (1) UA79674C2 (https=)
WO (1) WO2005006899A1 (https=)
ZA (1) ZA200505957B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment
CN117414361A (zh) * 2023-09-28 2024-01-19 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
WO2005006899A1 (en) 2005-01-27
CL2004001702A1 (es) 2005-05-13
ZA200505957B (en) 2006-11-29
TW200510424A (en) 2005-03-16
BRPI0412255A (pt) 2006-09-19
JP2006528171A (ja) 2006-12-14
EP1656183A1 (en) 2006-05-17
UA79674C2 (en) 2007-07-10
MXPA05014200A (es) 2006-07-03
GB0317227D0 (en) 2003-08-27
ATE380048T1 (de) 2007-12-15
EP1656183B1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
CN113474337A (zh) 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
CN113490666A (zh) 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
EP1149579A2 (en) Use of an estrogen agonist/antagonist for treating female sexual dysfunction
US20080153841A1 (en) Treatment of premature ejaculation
US8329656B2 (en) Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
JP2002541258A (ja) インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法
CN105473142A (zh) 用二氢吡嗪并-吡嗪治疗癌症
US20050049255A1 (en) Therapeutic combinations
JP2005519927A (ja) 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用
EP1656183B1 (en) Treatment of male sexual dysfunction
JP2008150371A (ja) 性機能障害を治療するための化合物
US20050026810A1 (en) Treatment of male sexual dysfunction
CA2584225A1 (en) Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
MXPA04012569A (es) Combinacion de inhibidores de fosfodiesteresa tipo 5(pde5) con antagonistas del receptor de angiotensina ii.
US20040132731A1 (en) Novel combination
EP1335730B1 (en) Use of pde5 inhibitors for the treatment of premature ejaculation
AU2002215149A1 (en) Treatment of premature ejaculation
HK40060213A (en) 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
HK40060210A (en) Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
HK1059043A (en) Treatment of premature ejaculation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued